Trendy Longevity Supplement Misses the Mark in Parkinson’s Trial

• A widely popular longevity supplement has failed to meet its primary endpoint in a clinical trial studying its effects on Parkinson’s disease.
• The results are a blow to supporters who have promoted the product as a way to slow aging and protect brain health.
• Researchers reported that the supplement did not produce the outcomes the study was designed to measure.
• The findings add to growing scrutiny of anti-aging products that have gained a large following without strong clinical evidence.

AI-generated briefing — triage, not the story; every claim links out to the coverage below.